CSPC Innovation Pharmaceutical Co., Ltd.

SZSE:300765 Stock Report

Market Cap: CN¥38.6b

CSPC Innovation Pharmaceutical Future Growth

Future criteria checks 5/6

CSPC Innovation Pharmaceutical is forecast to grow earnings and revenue by 37.5% and 36% per annum respectively. EPS is expected to grow by 34.3% per annum. Return on equity is forecast to be 13.7% in 3 years.

Key information

37.5%

Earnings growth rate

34.3%

EPS growth rate

Pharmaceuticals earnings growth19.1%
Revenue growth rate36.0%
Future return on equity13.7%
Analyst coverage

Good

Last updated06 Nov 2024

Recent future growth updates

Recent updates

Are CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) Investors Paying Above The Intrinsic Value?

Nov 21
Are CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) Investors Paying Above The Intrinsic Value?

Why CSPC Innovation Pharmaceutical's (SZSE:300765) Shaky Earnings Are Just The Beginning Of Its Problems

Oct 31
Why CSPC Innovation Pharmaceutical's (SZSE:300765) Shaky Earnings Are Just The Beginning Of Its Problems

Earnings Tell The Story For CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) As Its Stock Soars 27%

Sep 30
Earnings Tell The Story For CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) As Its Stock Soars 27%

Estimating The Fair Value Of CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765)

Aug 16
Estimating The Fair Value Of CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765)

CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) 27% Share Price Plunge Could Signal Some Risk

Jul 04
CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) 27% Share Price Plunge Could Signal Some Risk

CSPC Innovation Pharmaceutical's (SZSE:300765) Weak Earnings May Only Reveal A Part Of The Whole Picture

Apr 29
CSPC Innovation Pharmaceutical's (SZSE:300765) Weak Earnings May Only Reveal A Part Of The Whole Picture

CSPC Innovation Pharmaceutical (SZSE:300765) Will Pay A Larger Dividend Than Last Year At CN¥0.32

Apr 25
CSPC Innovation Pharmaceutical (SZSE:300765) Will Pay A Larger Dividend Than Last Year At CN¥0.32

CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) P/E Still Appears To Be Reasonable

Apr 24
CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) P/E Still Appears To Be Reasonable

Earnings and Revenue Growth Forecasts

SZSE:300765 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20265,1151,1161,5391,0856
12/31/20253,9878198521,0426
12/31/20242,4364001282726
9/30/20242,043513-85-21N/A
6/30/20242,129628-702-544N/A
3/31/20242,307705-404-344N/A
12/31/20232,502756832927N/A
9/30/20232,671591-313174N/A
6/30/20232,729659681910N/A
3/31/20232,804732667831N/A
1/1/20232,626726527641N/A
9/30/20222,694666294582N/A
6/30/20222,384562225461N/A
3/31/20222,034433113350N/A
1/1/20221,85039397292N/A
9/30/20211,333287167250N/A
6/30/20211,338284188277N/A
3/31/20211,319311201302N/A
12/31/20201,317300231349N/A
9/30/20201,329317246396N/A
6/30/20201,290316199344N/A
3/31/20201,270290228357N/A
12/31/20191,257273209315N/A
9/30/20191,299266163223N/A
6/30/20191,277251159233N/A
3/31/20191,281230140191N/A
12/31/20181,240224101160N/A
9/30/20181,14921468119N/A
6/30/20181,111198N/A49N/A
3/31/20181,064191N/A18N/A
12/31/20171,031195N/A1N/A
12/31/2016890207N/A137N/A
12/31/2015742116N/A112N/A
12/31/2014651108N/A93N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300765's forecast earnings growth (37.5% per year) is above the savings rate (2.8%).

Earnings vs Market: 300765's earnings (37.5% per year) are forecast to grow faster than the CN market (26.1% per year).

High Growth Earnings: 300765's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300765's revenue (36% per year) is forecast to grow faster than the CN market (13.9% per year).

High Growth Revenue: 300765's revenue (36% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 300765's Return on Equity is forecast to be low in 3 years time (13.7%).


Discover growth companies